Bibliography
- Mateos MV. Advances in the management of asymptomatic myeloma. Curr Opin Oncol 2014;26(6):670-6
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-48
- Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582-90
- Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785-9
- Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27(4):941-6
- Perez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010;148(1):110-14
- Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123(4):631-6
- Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123(1):78-85
- Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365(5):474-5
- Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013;27(3):680-5
- Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28(9):1606-10
- Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28(9):1902-8
- Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013;31(34):4325-32
- Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122(26):4172-81
- Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013;27(1):220-5
- Musto P, Petrucci MT, Bringhen S, et al. A multicenter randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113(7):1588-95
- Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369(5):438-47
- Mateos MV, Hernández MT, Giraldo P, et al. Long term follow-up on the treatment of high risk smoldering myeloma with lenalidomide plus low dex (Rd) (phase III Spanish trial): persistent benefit in overall survival. Blood (ASH Annual Meeting Abstracts) 2014;124(21):abstract 3465
- Landgren O, Roschewski M, Mailankody S, et al. Carfilzomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma: final results from the NCI phase 2 pilot study. Blood (ASH Annual Meeting Abstracts) 2014;124(21):abstract 4746
- Wang M, Nooka AK, Yee AJ, et al. Initial results of a phase 1/2a, dose escalation study of PVX-410 multi-peptide cancer vaccine in patients with smoldering multiple myeloma. (SMM). Blood (ASH Annual Meeting Abstracts) 2014;124(21):abstract 4737